Our published observations that phenylbutyrate (PBA), an HDAC inhibitor, attenuated amyloid plaque development in the PS1delta9/APPswe double transgenic mouse line and partially restored cognitive function [12], set the stage to further investigate HDAC inhibition as a viable approach to treat or prevent AD. This evidence concerns the gene HDAC9 and Alzheimer disease.